...
首页> 外文期刊>Pediatric Investigation >Plasma exchange therapy for acute necrotizing encephalopathy of childhood
【24h】

Plasma exchange therapy for acute necrotizing encephalopathy of childhood

机译:血浆交换治疗童年的急性坏死性脑病

获取原文
           

摘要

Importance Acute necrotizing encephalopathy (ANE) is a rare disease with high mortality. Plasma exchange (PLEX) has recently been reported to treat ANE of childhood (ANEC), but its efficacy is uncertain. Objective This study aimed to investigate the effectiveness of PLEX on ANEC. Methods A retrospective study was conducted in four pediatric intensive care units from December 2014 to December 2020. All patients who were diagnosed with ANEC were included; however, these patients were excluded if their length of stay was less than 24 h. Participants were classified into PLEX and non-PLEX groups. Results Twenty-nine patients with ANEC were identified, 10 in the PLEX group and 19 in the non-PLEX group. In the PLEX group, C-reactive protein, procalcitonin, alanine aminotransferase, and aspartate aminotransaminase levels were significantly lower after 3 days of treatment than before treatment (13.1 vs . 8.0, P = 0.043; 9.8 vs . 1.5, P = 0.028; 133.4 vs . 31.9, P = 0.028; 282.4 vs . 50.5, P = 0.046, respectively). Nine patients (31.0%, 9/29) died at discharge, and a significantly difference was found between the PLEX group and non-PLEX group [0 vs . 47.4% (9/19), P = 0.011]. The median follow-up period was 27 months, and three patients were lost to follow-up. Thirteen patients (50.0%, 13/26) died at the last follow-up, comprising three (33.3%, 3/9) in the PLEX group and ten (58.8%, 10/17) in the non-PLEX group, but there was no significant difference between the two groups ( P = 0.411). Three patients (10.3%, 3/29) fully recovered. Interpretation PLEX may reduce serum C-reactive protein and procalcitonin levels and improve liver function in the short term. PLEX may improve the prognosis of ANEC, and further studies are needed.
机译:重要性急性坏死性脑病(ANE)是一种罕见的死亡率。最近据报道了血浆交换(Plex)对待儿童(ANEC)的ANE,但其疗效是不确定的。目的本研究旨在调查Plex对ANEC的有效性。方法采用2014年12月至2020年12月的四个儿科重症监护单位进行了回顾性研究。包括诊断为ANEC的所有患者;但是,如果它们的逗留时间小于24小时,则排除这些患者。参与者被分类为Plex和非Plex组。结果鉴定了29例ANEC患者,10例在Plex组和19中的非PLEX组中的19例。在Plex基团中,在治疗前3天后,在治疗3天后显着降低C-反应蛋白,ProCalcitonin,丙氨酸氨基氨基酶和天冬氨酸氨基胺酶水平(13.1 Vs.8.0,P = 0.043; 9.8 Vs.1.5,P = 0.028; 133.4 vs。31.9,p = 0.028; 282.4 vs。50.5,p = 0.046)。九名患者(31.0%,9/29)在放电时死亡,Plex组和非Plex组之间发现了显着差异[0 VS。 47.4%(9/19),p = 0.011]。中位随访期为27个月,三名患者失去了随访。 13名患者(50.0%,13/26)在最后一次随访中死亡,包括在非PLEX组中的三(33.3%,3/9),10(58.8%,10/17),但两组之间没有显着差异(P = 0.411)。三名患者(10.3%,3/29)完全恢复。解释Plex可以减少血清C-反应蛋白和ProCalcitonin水平,并在短期内改善肝功能。 Plex可能改善ANEC的预后,需要进一步研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号